171 related articles for article (PubMed ID: 33460612)
1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease.
Sánchez Montero JM; Agis-Torres A; Solano D; Söllhuber M; Fernandez M; Villaro W; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Egea J; Martín MI; Girón R
Eur J Pharmacol; 2021 Mar; 895():173875. PubMed ID: 33460612
[TBL] [Abstract][Full Text] [Related]
2. Indazolylketones as new multitarget cannabinoid drugs.
González-Naranjo P; Pérez-Macias N; Pérez C; Roca C; Vaca G; Girón R; Sánchez-Robles E; Martín-Fontelles MI; de Ceballos ML; Martin-Requero A; Campillo NE; Páez JA
Eur J Med Chem; 2019 Mar; 166():90-107. PubMed ID: 30685536
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
Montanari S; Mahmoud AM; Pruccoli L; Rabbito A; Naldi M; Petralla S; Moraleda I; Bartolini M; Monti B; Iriepa I; Belluti F; Gobbi S; Di Marzo V; Bisi A; Tarozzi A; Ligresti A; Rampa A
Eur J Med Chem; 2019 Sep; 178():243-258. PubMed ID: 31185414
[TBL] [Abstract][Full Text] [Related]
4. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Pandey S; Singh BK
Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255
[TBL] [Abstract][Full Text] [Related]
5. Multiple Ligands Targeting Cholinesterases and β-Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore.
Szałaj N; Bajda M; Dudek K; Brus B; Gobec S; Malawska B
Arch Pharm (Weinheim); 2015 Aug; 348(8):556-63. PubMed ID: 26032855
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
[TBL] [Abstract][Full Text] [Related]
7. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Lange JH; Coolen HK; van der Neut MA; Borst AJ; Stork B; Verveer PC; Kruse CG
J Med Chem; 2010 Feb; 53(3):1338-46. PubMed ID: 20047331
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease.
Rampa A; Bartolini M; Pruccoli L; Naldi M; Iriepa I; Moraleda I; Belluti F; Gobbi S; Tarozzi A; Bisi A
Molecules; 2018 Jul; 23(8):. PubMed ID: 30061534
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
Rodríguez-Lavado J; Gallardo-Garrido C; Mallea M; Bustos V; Osorio R; Hödar-Salazar M; Chung H; Araya-Maturana R; Lorca M; Pessoa-Mahana CD; Mella-Raipán J; Saitz C; Jaque P; Reyes-Parada M; Iturriaga-Vásquez P; Pessoa-Mahana H
Eur J Med Chem; 2020 Jul; 198():112368. PubMed ID: 32388114
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease.
Dias KS; de Paula CT; Dos Santos T; Souza IN; Boni MS; Guimarães MJ; da Silva FM; Castro NG; Neves GA; Veloso CC; Coelho MM; de Melo IS; Giusti FC; Giusti-Paiva A; da Silva ML; Dardenne LE; Guedes IA; Pruccoli L; Morroni F; Tarozzi A; Viegas C
Eur J Med Chem; 2017 Apr; 130():440-457. PubMed ID: 28282613
[TBL] [Abstract][Full Text] [Related]
13. Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments.
Bautista-Aguilera ÓM; Ismaili L; Iriepa I; Diez-Iriepa D; Chabchoub F; Marco-Contelles J; Pérez M
Chem Rec; 2021 Jan; 21(1):162-174. PubMed ID: 33169934
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
15. Claulansine F-Donepezil Hybrids as Anti-Alzheimer's Disease Agents with Cholinergic, Free-Radical Scavenging, and Neuroprotective Activities.
Zang Y; Liu K; Wang W; Li C; Ma J; Yang J; Chen X; Wang X; Zhang D
Molecules; 2021 Feb; 26(5):. PubMed ID: 33671020
[TBL] [Abstract][Full Text] [Related]
16. Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, In Vitro Studies and Association with
Furqan T; Batool S; Habib R; Shah M; Kalasz H; Darvas F; Kuca K; Nepovimova E; Batool S; Nurulain SM
Biomolecules; 2020 May; 10(5):. PubMed ID: 32414087
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease.
Wang D; Hu M; Li X; Zhang D; Chen C; Fu J; Shao S; Shi G; Zhou Y; Wu S; Zhang T
Eur J Med Chem; 2019 Apr; 168():207-220. PubMed ID: 30822710
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti-Alzheimer's agents.
Shamsimeymandi R; Pourshojaei Y; Eskandari K; Mohammadi-Khanaposhtani M; Abiri A; Khodadadi A; Langarizadeh A; Sharififar F; Amirheidari B; Akbarzadeh T; Lotfian H; Foroumadi A; Asadipour A
Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800352. PubMed ID: 31136018
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors.
Modh RP; Kumar SP; Jasrai YT; Chikhalia KH
Arch Pharm (Weinheim); 2013 Nov; 346(11):793-804. PubMed ID: 24591157
[TBL] [Abstract][Full Text] [Related]
20. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
